Skip to content

Bariatric Arterial Embolization for Morbid Obesity

Bariatric Arterial Embolization for Morbid Obesity

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02786108
Acronym
BAEMO
Enrollment
50
Registered
2016-05-30
Start date
2016-05-31
Completion date
2018-05-31
Last updated
2016-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity

Keywords

left gastric artery, embolization, obesity

Brief summary

The purpose of this study is to evaluate the safety and effectiveness of left gastric artery embolization(bariatric arterial embolization) for morbid obesity. When the target vessel is blocked, some of the body's signals for feeling hungry will be suppressed and lead to weight loss. Although there are many ways to treat morbid obesity, surgery is currently the only effective method to be confirmed. But surgical treatment is likely to carry a high risk of treatment-related complications, such as fistula or intestinal obstruction, etc. This study is designed to help treat obesity using a method of transvascular interventional therapy, which is minimally invasive and non-surgical.

Interventions

BEHAVIORALhealthy diet and exercise

Sponsors

Zhongda Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Body mass index (BMI) \>30. 2. No history of gastrointestinal surgery. 3. Willing, able and mentally competent to provide written informed consent. 4. Suitable for protocol therapy as determined by the interventional radiology Investigator. 5. Adequate hematological, hepatic and renal function as follows: Hematological Neutrophils \> 1.5 x 109/L Platelets \> 100 x 109/L INR \<1.5 Hepatic Bilirubin ≤ 2.0 mg/dL Albumin ≥ 2.5 g/L Renal Estimated GFR \> 60ml/min.1.73m2 6. Aged between18 and 65 years old. 7. More than one year's follow-up can be obtained reliably

Exclusion criteria

1. Prior history of gastric pancreatic, hepatic, and/or splenic surgery 2. Prior embolization to the stomach, spleen or liver 3. Prior or current history of peptic ulcer disease 4. Significant risk factors for peptic ulcer disease including daily NSAID use and smoking. 5. Portal venous hypertension or cirrhosis 6. Less than 18 years or older than 65 years of age 7. Known aortic pathology such as aneurysm or dissection renal insufficiency as evidenced by an estimated glomerular filtration rate of \< 60 milliliters per minute an estimated glomerular filtration rate of \< 60 milliliters per minute 8. Major comorbidity such as cancer, significant cardiovascular disease, or peripheral arterial disease 9. Pregnant or intend to become pregnant within one year Known history of allergy to iodinated contrast media 10. Patients with certain psychiatric disorders such as schizophrenia, borderline personality disorder, and uncontrolled depression, and mental/cognitive impairment that limits the individual's ability to understand the proposed therapy. 11. Patients currently taking or requiring chronic use of NSAID or steroid medications

Design outcomes

Primary

MeasureTime frameDescription
Weight LossBaseline, post-op 1 month, 3 months, 6 months,9 months,12 monthsUnit of Measure: Percentage of excess weight loss \[%EWL\]. The body weight will be measured within 2-4h after breakfast.

Secondary

MeasureTime frameDescription
Lipid ProfileBaseline, post-op 1 month, 3 months, 6 months,9 months,12 monthsBlood cholesterol levels, triglyceride levels and lipoprotein levels will be detected. Unit of Measure: mmol/L.
Number of Patients with Adverse Eventspost-op 30 daysSurgical complications and adverse events such as massive hemorrhage, femoral artery pseudoaneurysm, gastric mucosal ischemia and necrosis and gastric perforation, etc., will be documented.
Ghrelin levelsBaseline, post-op 1 month, 3 months, 6 months,9 months,12 monthsUnit of Measure: pg/mL. Detection of serum Ghrelin levels will be obtained using fasting blood in the morning.
Blood pressureBaseline, post-op 1 month, 3 months, 6 months,9 months,12 monthsThe brachial artery blood pressure will be measured in the early hours of the morning and under the quiet situation. Unit of Measure: mmHg.
Leptin levelsBaseline, post-op 1 month, 3 months, 6 months,9 months,12 monthsDetection of serum Leptin levels will be obtained using fasting blood in the morning. Unit of Measure: pg/mL.
Results of Gastroendoscopic ExaminationBaseline, post-op 1 week, post-op 1 month, 3 months, 6 months,9 months,12 monthsPhotos and clinical reports will be analyzed.
Quality of Life Parameters Survey12 monthsN/A Utilizing SF-36/ pre and post procedure to determine the changes of quality in life; everyday activities.
Abdominal fat contentBaseline, post-op 1 month,6 months,12 monthsAbdominal fat content detected by MRI.

Countries

China

Contacts

Primary ContactZhibin Bai
baizhibin1004@sina.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026